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http://www.biomedcentral.com/1471-2407/14/223RESEARCH ARTICLE Open AccessOral cancer cells may rewire alternative metabolic
pathways to survive from siRNA silencing of
metabolic enzymes
Min Zhang1†, Yang D Chai1†, Jeffrey Brumbaugh1, Xiaojun Liu1, Ramin Rabii1, Sizhe Feng1, Kaori Misuno1,
Diana Messadi1,2 and Shen Hu1,2*Abstract
Background: Cancer cells may undergo metabolic adaptations that support their growth as well as drug resistance
properties. The purpose of this study is to test if oral cancer cells can overcome the metabolic defects introduced
by using small interfering RNA (siRNA) to knock down their expression of important metabolic enzymes.
Methods: UM1 and UM2 oral cancer cells were transfected with siRNA to transketolase (TKT) or siRNA to adenylate
kinase (AK2), and Western blotting was used to confirm the knockdown. Cellular uptake of glucose and glutamine
and production of lactate were compared between the cancer cells with either TKT or AK2 knockdown and those
transfected with control siRNA. Statistical analysis was performed with student T-test.
Results: Despite the defect in the pentose phosphate pathway caused by siRNA knockdown of TKT, the survived
UM1 or UM2 cells utilized more glucose and glutamine and secreted a significantly higher amount of lactate than
the cells transferred with control siRNA. We also demonstrated that siRNA knockdown of AK2 constrained the
proliferation of UM1 and UM2 cells but similarly led to an increased uptake of glucose/glutamine and production of
lactate by the UM1 or UM2 cells survived from siRNA silencing of AK2.
Conclusions: Our results indicate that the metabolic defects introduced by siRNA silencing of metabolic enzymes
TKT or AK2 may be compensated by alternative feedback metabolic mechanisms, suggesting that cancer cells may
overcome single defective pathways through secondary metabolic network adaptations. The highly robust nature
of oral cancer cell metabolism implies that a systematic medical approach targeting multiple metabolic pathways
may be needed to accomplish the continued improvement of cancer treatment.Background
The pentose phosphate pathway (PPP) is a biological
process that mainly functions to produce ribose-5-
phosphate for nucleic acid synthesis and to generate
nicotinamide adenine dinucleotide phosphate (NADPH)
[1]. There are two distinct branches of the pathway: the
oxidative PPP that converts glucose-6-phosphate into
pentose phosphate metabolites, and the non-oxidative
PPP that recycles pentose phosphates to glycolytic inter-
mediates or generates de novo ribose-5-phosphate from* Correspondence: shu@dentistry.ucla.edu
†Equal contributors
1UCLA School of Dentistry, 10083 Le Conte Ave, Los Angeles,
CA 90095-1668, USA
2UCLA Jonsson Comprehensive Cancer Center, 10083 Le Conte Ave,
Los Angeles, CA 90095-1668, USA
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orglycolytic intermediates. Transketolase (TKT) is one of
the rate-limiting enzymes in the PPP. Together with
transaldolase, TKT converts D-pentose (xylulose and ri-
bose) 5-phosphate into D-glyceraldehyde 3-phosphate
and D-fructose 6-phosphate, and TKT also utilizes these
glycolytic intermediates for de novo synthesis of ribose-
5-phosphate in the non-oxidative phase of PPP. In can-
cer cells, the PPP catalyzed by TKT plays an important
role in utilizing glucose for ribose-5-phosphate synthesis
[2]. Ribose-5-phosphate can be synthesized from the glyco-
lytic intermediates, fructose-6-phosphate and glyceraldehyde-
3-phosphate, via the non-oxidative branch of PPP or
from glucose-6-phosphate via the oxidative branch of
PPP. Previous studies have underlined the importance
of TKT for tumor cell metabolism, by demonstrating
that enhancement of TKT activity supports tumor cellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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like protein 1 (TKTL1) was identified as a possible mu-
tant form of human TKT [4]. The protein was found to
be over-expressed in multiple types of cancer tissues
[5-7] and contribute to a malignant phenotype through
increased glucose metabolism even in the presence of oxy-
gen and stabilization of hypoxia-inducible factor 1-alpha
(HIF-1α) [8]. Inhibition of TKTL1 gene expression in
tumor cells resulted in decreased cell growth and prolifer-
ation as well as reduced glucose metabolism and lactate
production [9]. In addition, TKTL1 is indispensable for
the function of the p53-dependent effector TIGAR (Tp53-
induced glycolysis and apoptosis regulator) on hypoxia-
induced cell death [10], and its expression correlates with
HIF-1α expression and is induced upon hypoxic condi-
tions which facilitate energy supply to tumors under these
circumstances [10]. These findings have demonstrated
TKTL1 may play an important role in the pathophysiology
of malignant tumors.
Adenylate kinases (AKs) represent a set of enzymes that
catalyze a reversible high-energy phosphoryl transfer
reaction between adenine nucleotides [11]. So far, six AK
isozymes, AK1, AK2, AK3, AK4, AK5, and AK6, were
identified. AK1 is localized in neuronal processes, sperm
tail and on the cytoskeleton in cardiac cells at high con-
centrations whereas AK2 is expressed in the intermem-
brane space, and AK3 and AK4 are localized in the
mitochondrial matrix. AK3 is expressed in all tissues
except for red blood cells suggesting that AK3 gene is a
housekeeping-type gene. However, AK4 is tissue-specific,
mainly expressed in kidney, brain, heart, and liver while
AK5 is solely expressed in a limited area of brain [12-14].
AK2 is a crucial component of this AK relay mechanism,
unique in its localization, and it functions to maintain low
cytosolic AMP concentrations as it primarily utilizes and
sequesters AMP [11]. During periods of metabolic stress,
AK2 increases the amount of available AMP and therefore
the AMP:ATP ratio, which activates downstream ATP-
sensing mechanisms – such as AMP-activated protein
kinase (AMPK) – to regulate cellular metabolism. AK2
gene mutation has been found in patients with reticular
dysgenesis, a most severe form of SCID (human severe
combined immunodeficiencies) which may lead to bilat-
eral sensorineural deafness in affected newborns. AK2 is
specifically expressed in the stria vascularis region of the
inner ear, providing an explanation of the sensorineural
deafness in these individuals [15,16]. AK2 is also essential
for the development of Drosophila melanogaster [17] as
well as in the process of cardiac stem cell differentiation/
cardiogenesis. Knockdown of AK1, AK2 and AK5 activ-
ities with siRNA disrupted cardiogenesis whereas induc-
tion of creatine kinase, the alternate phosphotransfer
pathway, compensated for AK-dependent energetic deficit
[18]. In addition, human immunodeficiency virus type 1(HIV-1) encoded viral protein Vpr was found to induce
the expression of enzymes in the glycolytic pathway
(pentose phosphate and pyruvate metabolism) whereas
down-regulate AK2 and TKT [19]. While AK2 is a sig-
nificant component of cellular metabolism and adap-
tion, it has not yet been linked to oral cancer. Previous
studies have demonstrated a biochemical difference of
AK2 in lung tumors, but evidence of its role in other
types of cancers is limited [20,21].
The purpose of this study is to test if oral cancer cells
can overcome the defects introduced by using small
interfering RNA (siRNA) to knock down important
metabolic enzymes. siRNA silencing of TKT or AK2 was
performed on UM1 and UM2 oral cancer cells, which
were both derived from a same tongue squamous cell
carcinoma, and the effects of their inhibition on cell
proliferation, cellular uptake of glucose and glutamine
and lactate production were investigated.Methods
Cell lines and cell culture
Normal human oral keratinocytes (NHOKs) were main-
tained in EpiLife media supplemented with the human
keratinocyte growth supplement (Invitrogen, Carlsbad,
CA, USA). UM1 and UM2 oral cancer cell lines [22] were
cultured in Dulbecco’s modified eagle medium (DMEM)
plus 10% fetal bovine serum, penicillin (100 U/mL), and
streptomycin (100 μg/mL). The cells were maintained at
37°C in a humidified 5% CO2 incubator and passaged
when they reached 90-95% confluence.siRNA knockdown of TKT or AK2
UM1 and UM2 cells were transfected with siRNA in 96-
well or 6-well plates using the Hilymax transfection regent
(HilyMax, Rockville, MD, USA) according to the com-
pany’s instruction. Validated double-stranded siRNAs of
TKT (sc-45591) and AK2 (sc-38906) or non-target control
siRNAs (Santa Cruz Biotech, Santa Cruz, CA, USA) were
mixed with the transfection reagent and then added to the
cell culture. After 24-hour treatment, the siRNAs were re-
moved and the cells were further cultured in fresh media
for 48 hours. Both siRNAs are a pool of three different
siRNA duplexes. TKT siRNA (sc-45591A): Sense: CCU
ACACCGGCAAAUACUUtt, Antisense: AAGUAUUU
GCCGGUGUAGGtt; TKT siRNA (sc-45591B): Sense:
GCAUCUAUAAGCUGGACAAtt; Antisense: UUGUC
CAGCUUAUAGAUGCtt; TKT siRNA (sc-45591C):
Sense: CUUCUCGGAGAUCUUCAAAtt; Antisense: UUU
GAAGAUCUCCGAGAAGtt. AK2 siRNA (sc-38906A):
Sense: GAAGCUUGAUUCUGUGAUUtt; Antisense: AAU
CACAGAAUCAAGCUUCtt; AK2 siRNA (sc-38906B):
Sense: CCAGCCAGUUAGUUAUUCAtt; Antisense: UGA
AUAACUAACUGGCUGGtt; AK2 siRNA (sc-38906C):
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UACAUCAAGCAAGUGCtt.
Cell proliferation assay
Cell proliferation assays were performed at 72 hours
post-transfection using the CellTiter 96® aqueous non-
radioactive MTT cell proliferation kits (Promega, Madi-
son, WI, USA). Briefly, 20ul of the MTT/PMS mix was
added to each well of the 96-well plate and incubated at
37°C in CO2 incubator for 60 min. The absorbance was
read at 490 nm with a 96-well plate reader (BioTek
Instruments, Winooski, VT, USA). Cell numbers were
counted at 72 hours post-transfection using trypan-blue
exclusion assay.
Glucose assay
UM1 and UM2 cells were transfected with TKT siRNA
(siTKT), AK2 siRNA (siAK2) or control siRNA (siCTRL)
as described above. At 72 hours post-transfection, the
transfected cells were incubated with complete culture
media, and the concentration of the remaining glucose
in the culture media was measured with a glucose assay
kit (BioVision, Mountain View, CA, USA). Briefly, the
media ware de-proteinized with a 10-KDa ultracentrifuge
filter unit (Millipore, Billerica, MA, USA). The media were
then diluted with phosphate buffer saline and subjected to
enzymatic reactions at 37°C for 30 min in the dark, and
then the absorbance was read at 570 nm with the 96-well
plate reader (BioTek).
Lactate assay
Similarly, the culture media for siRNA-transfected cells
were harvested for lactate assay. The lactate in the
culture media was measured with a colorimetric lactate
assay kit (BioVision). The reactions were incubated at
37°C for 30 min in the dark, and then the absorbance
was read at 570 nm with the 96-well plate reader.
Glutamine assay
The remaining levels of glutamine in the culture media
were measured with a glutamine assay kit (BioAssay
Systems, Hayward, CA, USA). The culture media were
first de-proteinized with a 10-KDa ultracentrifuge filter
unit, and then incubated with the enzyme mix at room
temperature for 40 min in the dark. The absorbance was
read at 565 nm with the 96-well plate reader.
Western blotting
Protein samples were separated with a 4-12% Bis-Tris
NuPAGE gel (Invitrogen, Carlsbad, CA, USA) and trans-
ferred onto nitrocellulose membrane by Trans-blot SD
semi-dry transfer cell (Bio-Rad, Hercules, CA, USA). The
membrane was then blocked with 5% non-fat dry milk
(Santa Cruz, USA) for one hour, and then sequentiallyincubated with anti-TKT (H50, sc-67120) or anti-AK2
(H65, sc-28786) primary antibody (Santa Cruz Biotech,
Santa Cruz, CA, USA) and corresponding secondary anti-
body (GE Healthcare, Piscataway, NJ, USA). The detection
was performed with the ECL-Plus Western blotting re-
agent kit (GE Healthcare).
Results
Knockdown of TKT or AK2 expression in UM1 and UM2
oral cancer cells
To investigate if TKT is abnormally expressed in oral can-
cer cells, we compared the endogenous expression levels
of TKT among NHOKs, UM1 and UM2 cell lines. Both
UM1 and UM2 cancer cell lines were initially established
from a same tongue squamous cell carcinoma. However,
UM1 cells appear to be highly invasive whereas UM2 cells
are low invasive [22]. Western blot analysis indicated that
TKT expression was slightly over-expressed in the
UM1 and UM2 cancer cells when compared to NHOKs
(Figure 1A). In order to assess the effects of TKT
down-regulation on cellular uptake of glucose and glu-
tamine, we used siRNA to knock down TKT expression
in the UM1 and UM2 cells. As shown in Figure 1,
siTKT transfection led to a significant decline in the
expression of TKT in both UM1 and UM2 cancer cells.
AK2 was over-expressed in the oral cancer cells, espe-
cially in low invasive UM2 cells, when compared to
NHOKs (Figure 2A). With siAK2 transfection, the expres-
sion of AK2 was successfully inhibited in both UM1 and
UM2 cells (Figure 2B). It was also demonstrated that
knockdown of TKT did not affect AK2 expression, and
conversely knockdown of AK2 did not impact the expres-
sion of TKT. However, knockdown of ASCT2, which is a
glutamine transporter, suppresses the expression of AK2
in UM1 cells (Figure 2C). siRNA silencing was also
attempted to knock down the expression of TKT and AK2
in NHOKs. However, the normal keratinocytes did not
survive from the siRNA transfection experiments.
Effect of TKT or AK2 knockdown on the proliferation of
UM1 and UM2 cells
To study the effect of down-regulation of TKT or AK2 on
cell proliferation, UM1 and UM2 cells were transfected
with either siTKT (or siAK2) or scrambled siCTRL and
then harvested at 72 hours post-transfection for cell
proliferation assays. As shown in Figure 3, the siTKT-
transfected UM1 cells displayed a 33% reduction in cell
proliferation (MTT assay) when compared to the cells
transfected with siCTRL (p = 0.003), and the UM2 cells
exhibited a 23% reduction in proliferation (p = 0.003). As
for cell viability (trypan-blue exclusion) assays, a reduction
of 30% was observed in siTKT-transfected UM1 cells (p =
0.004) and a reduction of 35% was observed in siTKT-
transfected UM2 cells (p = 0.02).
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UM1 cells    siCTRL  siASCT2  siTKT 
-Actin 
AK2  
TKT  UM2 cells     siCTRL     siTKT 
TKT  
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B C
Figure 1 Knockdown of TKT expression in UM1 and UM2 oral cancer cells with siRNA. (A) Western blot analysis of TKT protein expression in
NHOKs, UM1 and UM2 oral cancer cells. (B) Western blot analysis of TKT and AK2 expression in UM1 cells transfected with control siRNA (siCTRL), TKT
siRNA (siTKT) or ASCT2 siRNA (siASCT2). (C) Western blot analysis of TKT in UM2 cells transfected with siTKT or siCTRL.
AK2  
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AK2  
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UM1 cells    siCTRL      siAK2   
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 NHOK   UM1   UM2
Figure 2 siRNA knockdown of AK2 expression in UM1 and UM2 oral cancer cells. (A)Western blot analysis of AK2 protein expression in NHOKs,
UM1 and UM2 oral cancer cells. (B) Western blot analysis of AK2 expression in UM1 and UM2 cells transfected with siCTRL or siTKT. (C) Western blot
analysis of AK2 and TKT in UM1 cells transfected with siCTRL, siAK2 or siASCT2.
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Figure 3 Effect of siRNA knockdown of TKT on the proliferation of UM1 and UM2 cells. siRNA silencing of TKT significantly inhibited the
proliferation of UM1 cells (n = 4) and UM2 cells (n = 4).
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nificantly inhibited when the cells were transfected with
siAK2. When compared to siCTRL-transfected cells,
siAK2-transfected UM1 cells exhibited a 23% decrease
of proliferation (p = 0.01), while siAK2-transfected UM2
cells showed a 24% decline in their proliferation (p =
0.003) (Figure 4). Similarly, significant reductions in
viable cell numbers (trypan-blue exclusion assay) were0 
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Figure 4 Effect of siRNA knockdown of AK2 on the proliferation of UM
proliferation of UM1 (n = 4) and UM2 (n = 4) cells.observed in siAK2-transfected UM1 (29%, p = 0.02) and
UM2 cells (25%, p = 0.03).
Effect of TKT knockdown on the glucose uptake and
lactate production by UM1 and UM2 cells
To investigate the effect of TKT and AK2 knockdown
on the glucose uptake of UM1 and UM2 cells, we trans-
fected the cells with siTKT, siAK2 or siCTRL and then0 
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1 and UM2 cells. siRNA knockdown of AK2 significantly inhibited the
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growth media. Afterwards, the culture media were
collected for glucose and lactate assays to determine the
glucose uptake as well as the lactate production.
As shown in Figure 5, siTKT-transfected UM1 cells con-
sumed 1.24-fold higher amount of glucose (p = 0.01) than
the cells transfected with scrambled siCTRL, while UM2
cells utilized 1.39-fold higher levels of glucose (p = 0.003).
Meanwhile, siTKT-transfected UM1 cells produced
1.54-fold more of lactate (p = 0.0006) whereas siTKT-
transfected UM2 cells produced 1.44-fold more of lactate
(p = 0.0001), which corroborates with the observation of
increased glucose uptake by siTKT-transfected cells.Effect of AK2 knockdown on the glucose uptake and
lactate production by UM1/UM2 cells
Glucose depletion assays were also performed to deter-
mine the glucose uptake by siAK2-transfected UM1 and
UM2 cells (Figure 6). The siAK2-transfected UM1 cells
utilized 1.44-fold more of glucose (p = 0.002) than the
UM1 cells transfected with siCTRL, and the siAK2-
transfected UM2 cells consumed a 1.26-fold more of glu-
cose (p = 0.03). Similar to the TKT-transfected UM1 cells,
the AK2-transfected UM1 cells secreted a 1.25-fold higher
amount of lactate (p = 0.02), consistent with the increased
uptake of glucose by the cells. However, there was only a
slight increase of 1.13-fold in lactate production by the
AK2-transfected UM2 cells (p = 0.09).UM1 siCTRL UM1 siTKT 
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Figure 5 Effect of siRNA knockdown of TKT on glucose uptake and lacta
by UM1 (n = 5, p = 0.01) and UM2 (n = 5, p = 0.0003) cells when TKT expressi
UM1 (n = 5, p = 0.0006) and UM2 cells (n = 5, p = 0.0001) produced significanEffect of TKT or AK2 knockdown on the glutamine uptake
by UM1 and UM2 cells
As shown in Figure 7, the siTKT-transfected UM1 cells
utilized 2.23-fold higher amount of glutamine (p = 0.01)
than the UM1 cells transfected with scrambled siCTRL,
while the siTKT-transfected UM2 cells utilized 1.7-fold
higher amount of glutamine (p = 0.02) than the siCTRL-
transfected UM2 cells. Similarly, the siAK2-transfected
UM1 cells consumed 1.99-fold more of glutamine (p =
0.02) than the siCTRL-transfected UM1 cells, whereas
the siAK2-transfected UM2 cells consumed 1.25-fold
more of glutamine (p = 0.03) than the UM2 cells trans-
fected with scrambled control siRNA.
Discussion
Tumor cell proliferation requires rapid synthesis of bio-
molecules such as nucleic acids, proteins and lipids. The
metabolism of such tumor cells deviates from the norm,
re-programmed to facilitate the uptake of nutrients such
as glucose and glutamine for de novo synthesis of bio-
molecules. TKT, a critical metabolic enzyme in the non-
oxidative branch of PPP, catalyzes reactions that enable
oxygen-independent glucose degradation and that play a
crucial role in the biosynthesis of ribose-5-phosphate in
tumor cells. Our study demonstrates that siRNA knock-
down of endogenous TKT expression significantly im-
pairs the proliferation of the UM1 and UM2 oral cancer
cells. The resultant limitation of UM1 and UM2 growth
stems from the severe defects in the PPP caused byUM2 siCTRL UM2 siTKT 
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Figure 6 Effect of AK2 knockdown on the glucose uptake and lactate production by UM1 and UM2 cells. A significantly higher amount of
glucose was consumed by UM1 cells (n = 5, p = 0.002) and UM2 cells (n = 5, p = 0.03) when cellular AK2 expression was inhibited by siRNA.
Meanwhile, siAK2-transfected UM1 (n = 5, p = 0.02) and UM2 cells (n = 5, p = 0.09) produced more lactate than the siCTRL-transfected cells.
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phosphate, nucleotides and possibly precursors for other
biomolecules. Due to siRNA silencing of TKT in these
cells, ribose-5-phosphate may have to be mainly synthe-
sized from the glycolytic intermediate glucose-6-
phosphate via the oxidative branch of PPP. However,
this pathway alone is less efficient in the synthesis of
ribose-5-phosphate, contributing to a reduced proliferationUM1 siCTRL UM1 siTKT 
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Figure 7 Effect of siRNA knockdown of TKT or AK2 on the glutamine
glutamine was consumed by siTKT-transfected UM1 (n = 4, p = 0.01) and U
cells. Similarly, siAK2-transfected UM1 (n = 4, p = 0.02) and UM2 (n = 4, p =
the siCTRL-transfected cells.rate of the cells. Meanwhile, PPP involves the biosynthesis
of glycolytic intermediates such as fructose-6-phosphate
and glyceraldehyde-3-phosphate, which are normally
recycled by glycolytic process. Silencing TKT in the cancer
cells obviously abolish the cross-talk between PPP and gly-
colysis, causing deficiency in utilizing glycolytic metabolites
for down-stream biosynthesis and energy production in
the cells.UM2 siCTRL UM2 siTKT 
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uptake by UM1 and UM2 cells. A significantly higher amount of
M2 (n = 4, p = 0.02) cells when compared to the siCTRL-transfected
0.03) cells consumed a significantly higher amount of glutamine than
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http://www.biomedcentral.com/1471-2407/14/223When compared to the cells transfected with scrambled
control siRNA, the cells transfected with siTKT also
display an increased uptake of glucose. The high level of
glycolysis is required to confer metabolic adaption when
facing defects in the PPP, providing not only ATP for the
tumor cells’ high bioenergetic demands, but also increas-
ingly needed precursors for the synthesis of biomolecules.
Consistent with the results of increased glucose uptake
and glycolysis, higher levels of lactate production were ob-
served in the cells with TKT knockdown. When endogen-
ous TKT expression is inhibited by siRNA, UM1 and
UM2 cells also uptake a markedly higher amount of
glutamine. Glutamine and its degradation products, glu-
tamate and aspartate, are precursors for de novo synthesis
of nucleotides and proteins. Our study suggests that, to
survive from TKT silencing, UM1 and UM2 cells increas-
ingly utilize glucose and glutamine to rescue the production
of ribose-5-phosphate, nucleotides and other biomole-
cules. In addition to composing the structural units of
nucleic acids, nucleotides play a central role in metabolism
by serving as sources of biochemical energy, such as ATP
and GTP. It is thus possible that an increase in the uptake
and metabolism of glucose and glutamine contributes to
maintaining the chemical energy in the cancer cells.Kreb cycle
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Figure 8 A schematic diagram of possible metabolic network adaptat
silencing of TKT or AK2. (A) siRNA silencing of TKT may possibly result in
cancer cells. Compensation of TKT by TKTL1 may be involved in this metab
linked to increased glucose uptake and lactate production in cancer cells. (
activating AMPK and glycolysis.Recently, Zhao et al. demonstrated that inhibition of
TKT led to a dramatic growth inhibition of imatinib-
resistant cancer cells, but co-expression of TKTL1 in
those cancer cells prevented the growth inhibitory effect
of TKT suppression. When imatinib-resistant cells were
first stably expressed with TKTL1 that lacks the TKT
shRNA sequence, the transfection of the TKT shRNA
plasmid had no effect on the ability of cells to grow in
the presence of both imatinib and puromycin [23].
These results are in line with the findings from our
study. Since TKTL1 activity has been linked to increased
glucose uptake and lactate production in cancer cells
[8-10], the increased glucose uptake and lactate produc-
tion observed in our study may be due to increased
TKTL1 activity to compensate knockdown of TKT.
Comparable to the results obtained with the TKT
knockdown study, the siRNA knockdown of AK2 also
impairs the proliferation of UM1 and UM2. Due to its
unique localization in the mitochondrial intermembrane
space, the crucial function of AK2 in maintaining AMP:
ATP ratios cannot be compensated by other ADK iso-
zymes. Because AK2 primarily utilizes AMP to produce
ADP and eventually ATP, its knock-down will inhibit the
ability of the cell to generate ATP, resulting in anO
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http://www.biomedcentral.com/1471-2407/14/223increased AMP:ATP ratio. Consequently, AMPK, a kinase
sensitive to AMP:ATP ratios, is activated to regulate cellu-
lar energetics and restore energy homeostasis through the
phosphorylation of many downstream targets [24,25]. The
overall effect of AMPK activation results in the reduced
proliferation of UM1 and UM2, as it is well established
that AMPK deters cell growth and down-regulates
anabolic pathways, such as protein and lipid synthesis, in
order to conserve ATP [26].
While AMPK acts to conserve ATP through a reduction
in cell growth and proliferation, its activation also results
in the up-regulation of energy-producing catabolic path-
ways, including glycolysis [24,26]. The UM1 and UM2
cells transfected with siAK2 display an elevated consump-
tion of glucose and glutamine, both essential for the pro-
duction of cellular energy. AMPK has been referred to as
a “master switch” of metabolism and glycolysis, and it has
been indicated in studies of tumor cells that AMPK highly
regulates cellular glycolytic flux [24,27]. The increased
levels of lactate production serve as an indicator of the
increased level of glycolysis, and it has been noted that
greater concentrations of lactate can further stimulate
AMPK activity [27]. While AMPK has an established and
well-studied role in cancer, it has not been previously
linked with AK2 in this context, and recently investigated
functions of AMPK in regulating cell energy metabolism
and tumor cell survival are still emerging [28].
Conclusion
In this study, we have demonstrated that the knockdown
of TKT or AK2 expression significantly inhibits the prolif-
eration of oral cancer cells. Due to deficiencies in the PPP
caused by siRNA silencing of TKT, UM1 and UM2 cells
displayed an increasing uptake of glucose and glutamine,
and consequently produced a higher amount of lactate.
These findings suggest that the partial inactivation of the
non-oxidative PPP due to siRNA silencing of TKT was
compensated by the activation of alternative modes of me-
tabolism, possibly including glycolysis, TKTL1-mediated
non-oxidative PPP and oxidative PPP (Figure 8). With the
siRNA silencing of AK2, depletion of ATP and an increase
of the AMP:ATP ratio may activate AMPK as a master
regulatory metabolic control, both down-regulating ana-
bolic pathways to preserve ATP and up-regulating cata-
bolic mechanisms to generate ATP. Thus, the defects
in the ATP-producing capacity and phosphoryl relay
mechanism of AK2 may be compensated by alternative
metabolic pathways initiated by AMPK (Figure 8). The
implication of our study is that cancer cells, as a system,
can rewire alternative pathways for biosynthesis when one
of the biosynthetic pathways is truncated or suppressed.
The highly robust nature of cancer cell metabolism can
logically complicate cancer treatment since therapeutic
intervention targeting one of the metabolic pathwayscannot prevent cancer cells from utilizing other pathways
for biosynthesis and proliferation. As such, a more com-
prehensive, systematic medical approach targeting mul-
tiple metabolic pathways may be needed to accomplish
the continued improvement of cancer treatment.
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